{"filing":{"accession_number":"0001193125-26-402820","cik":"0001623526","ticker":"STOK","company_name":"Stoke Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-25","report_date":"2026-09-22","primary_document":"d136438d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1623526/000119312526402820/d136438d8k.htm"},"events":[{"id":35099,"run_id":32322,"accession_number":"0001193125-26-402820","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses both a director departure (Edward M. Kaye's resignation effective September 23, 2026) and a director appointment (Alexander Bo Cumbo appointed to the Board as a Class III director on the same date). While both events occurred, the principal disclosed action centers on the appointment of Cumbo to fill the vacancy, supported by detailed disclosure of his compensation (annual cash retainer of $45,000 and an initial stock option grant valued at approximately $724,000). The appointment is material as it affects board composition and governance.","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-09-25","form":"8-K","submitted_at":null,"items":[{"id":39031,"accession_number":"0001193125-26-402820","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director departure (Edward M. Kaye's resignation effective September 23, 2026) and a director appointment (Alexander Bo Cumbo appointed to the Board as a Class III director on the same date). While both events occurred, the principal disclosed action centers on the appointment of Cumbo to fill the vacancy, supported by detailed disclosure of his compensation (annual cash retainer of $45,000 and an initial stock option grant valued at approximately $724,000). The appointment is material as it affects board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T20:10:45.711162+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39031,"accession_number":"0001193125-26-402820","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director departure (Edward M. Kaye's resignation effective September 23, 2026) and a director appointment (Alexander Bo Cumbo appointed to the Board as a Class III director on the same date). While both events occurred, the principal disclosed action centers on the appointment of Cumbo to fill the vacancy, supported by detailed disclosure of his compensation (annual cash retainer of $45,000 and an initial stock option grant valued at approximately $724,000). The appointment is material as it affects board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T20:10:45.711162+00:00","company_name":"Stoke Therapeutics, Inc.","ticker":"STOK","filing_date":"2026-09-25"}]}